Trulieve Cannabis Corp, a leading and top-performing cannabis company in the U.S., today announced that it has filed applications with the U.S. Drug Enforcement Administration (DEA) to register certain state‑licensed medical marijuana operations pursuant to the expedited registration pathway established by the recent rescheduling of medical marijuana to Schedule III under the Controlled Substances Act.

“DEA registration for our medical business marks a historic step forward for Trulieve and the patients we serve,” said Trulieve Chief Executive Officer Kim Rivers. “With over 200 dispensaries serving only medical patients, Trulieve is uniquely positioned to set the bar as a responsible operator in U.S. cannabis.”

Following the reclassification of medical marijuana to Schedule III, the DEA established an expedited registration process for eligible state‑licensed medical marijuana operators. For operators that apply within 60 days, licensure to manufacture, distribute, and dispense Schedule III medical marijuana products is deemed approved unless otherwise notified.

Trulieve is a vertically integrated, multi-state marijuana company operating in several U.S. markets, with major hubs in the Northeast, Southeast and Southwest. The company’s key markets include Arizona, Florida, Ohio and Pennsylvania.

Trulieve focuses on expanding access to marijuana through a range of branded products and retail experiences. The company has built scaled operations in multiple markets and continues to pursue growth through its hub-based expansion strategy.

Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.